The expression of PCSK9 is deregulated in different types of cancers, including HCC neuroglioma, breast cancer, colorectal cancer and others [4,9], highlighting a major question about the therapeutic strategies that could be adopted to target PCSK9 in these cancers. Here, PCSK9 is linked to colorectal cancer.